Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 14, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 14, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $495.02 ($158,407) on August 14, 2026; holds 333,623 after (Indirect).
- Open-market sale: disposed of 414 Common Stock at $495.96 ($205,329) on August 14, 2026; holds 333,209 after (Indirect).
- Open-market sale: disposed of 537 Common Stock at $497.22 ($267,007) on August 14, 2026; holds 332,672 after (Indirect).
- Open-market sale: disposed of 2,130 Common Stock at $498.39 ($1,061,580) on August 14, 2026; holds 330,542 after (Indirect).
- Open-market sale: disposed of 3,630 Common Stock at $499.30 ($1,812,446) on August 14, 2026; holds 326,912 after (Indirect).
- Open-market sale: disposed of 2,148 Common Stock at $500.05 ($1,074,099) on August 14, 2026; holds 324,764 after (Indirect).
- Open-market sale: disposed of 321 Common Stock at $500.93 ($160,797) on August 14, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on August 14, 2026; holds 132,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,739,664 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-08-14 | Open-market sale | Common Stock | 320 | $495 | $158.4K | 333,623 |
| 2026-08-14 | Open-market sale | Common Stock | 414 | $496 | $205.3K | 333,209 |
| 2026-08-14 | Open-market sale | Common Stock | 537 | $497 | $267.0K | 332,672 |
| 2026-08-14 | Open-market sale | Common Stock | 2,130 | $498 | $1.1M | 330,542 |
| 2026-08-14 | Open-market sale | Common Stock | 3,630 | $499 | $1.8M | 326,912 |
| 2026-08-14 | Open-market sale | Common Stock | 2,148 | $500 | $1.1M | 324,764 |
| 2026-08-14 | Open-market sale | Common Stock | 321 | $501 | $160.8K | 324,443 |
| 2026-08-14 | Option exercise/conversion | Stock Option | 9,500 | — | — | 132,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Option exercise/conversion (9,500 shares) |
| 2026-08-14 | Open-market sale (320 shares) |
| 2026-08-14 | Open-market sale (414 shares) |
| 2026-08-14 | Open-market sale (537 shares) |
| 2026-08-14 | Open-market sale (2,130 shares) |
| 2026-08-14 | Open-market sale (3,630 shares) |
| 2026-08-14 | Open-market sale (2,148 shares) |
| 2026-08-14 | Open-market sale (321 shares) |
| 2026-08-14 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.